1. 1 ICON Plc. Jefferies 3rd Annual Healthcare Conference June 2009

2. 2 Certain statements contained herein including, without limitation, statements containing the words “believes,” “anticipates,” “intends,” “expects” and words of similar import, constitute forward-looking statements concerning the Company's operations, performance, financial condition and prospects. Because such statements involve known and unknown risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward Looking Statements

3. 3 Global Full Service Clinical Development US 45% EU 47% ROW 8%

4. 4 ICON’s Global Footprint

5. 5 ICON plc Staff Growth 1990 - Today

6. 6 Market Environment

7. 7 Market Fundamentals still intact Outsourcing Penetration expected to increase ¯ More Strategic approach to outsourcing ¯ Cost containment ¯ Globalisation of clinical research Continued R&D Spending Growth. ¯ Pipelines remain solid ¯ Scientific innovation continues to expand Increasing Regulation ¯ More patients/ more studies ¯ Post marketing surveillance

8. 8 Clients are increasingly focused on their core competencies of ¯ Discovery ¯ Strategic Development ¯ Marketing Clients are engaging CROs at a more strategic level ¯ Level of management engagement (Executive to executive) ¯ Level of co-operative engagement i.e. sharing drug pipeline intentions ¯ Deeper reliance on CRO scientific and therapeutic expertise Reduced internal capacity in the companies of strategic partners e.g. staff or asset transfers/reductions Clients likely to move their % outsourced from ≈ 30% to >50% over the next 5+ years Increased Outsourcing

9. 9 Market Fundamentals still intact Outsourcing Penetration expected to increase ¯ More Strategic approach to outsourcing ¯ Cost containment ¯ Globalisation of clinical research Continued R&D Spending Growth. ¯ Pipelines remain solid ¯ Scientific innovation continues to expand Increasing Regulation ¯ More patients/ more studies ¯ Post marketing surveillance

10. 10 Clinical Compounds in Development

11. 11 R&D Spending Growth

12. 12 CRO Market Size (1996-2012E)

13. 13 Total Biotech Funding (In Millions USD$) Source: Burrill and Company

14. 14 Market Fundamentals still intact Outsourcing Penetration expected to increase ¯ More Strategic approach to outsourcing ¯ Cost containment ¯ Globalisation of clinical research Continued R&D Spending Growth. ¯ Pipelines remain solid ¯ Scientific innovation continues to expand Increasing Regulation ¯ More patients/ more studies ¯ Post marketing surveillance

15. 15 Opportunities…. but also Risks

16. 16 ICON in this Market Environment

17. 17 Gross and Net Volume of RFPs 2003 to Q1 2009 Net volume represents only those opportunities which were ultimately outsourced

18. 18 Gross and Net Value of RFPs 2003 to Q1 2009 Net volume represents only those opportunities which were ultimately outsourced

19. 19 Net New Business wins and book to bill ratios Net Business Wins Book to Bill Ratio

20. 20 Analysis of Business Wins Q1 09 Net Wins 53% Large Pharma 2008 Net Wins Large Pharma Large Bio Mid Pharma Mid Bio Small Bio and Small Pharma 50% 13% 18% 12% 7% 68% 7% 18% 6%

21. 21 Analysis of Backlog by Client at the end of Q1 09 53% Large Pharma Large Pharma Large Bio Mid Pharma Mid Bio Small Bio and Small Pharma 53% 16% 17% 2% 12%

22. 22 Total Backlog levels. ($ millions)

23. 23 Coverage of next 4 quarters from backlog Value of backlog forecast to be earned in next 4 quarters % coverage of next 4 quarters forecast revenues

24. 24 Projects of longer duration leads to slower backlog burn

25. 25 Strategy

26. 26 Capitalise on market fundamentals to drive organic growth in all business units. Cross-sell services to grow sales and margin Build Deep Strategic Relationships Create Stronger differentiation across our services Retain a flexible business model to respond to differing client outsourcing strategies Pursue acquisitions to enhance depth and scale of current operations and to add additional complementary services e.g. Phase I Bioanalytical / Biomarkers Therapeutic specialists ICON’s Core Strategy is Organic Growth, with acquisitions made to add new services or scale. Acquisitions to date - 13 Revenues acquired $130m Staff acquired – 1,200 => Organic growth >80% Safety / Late Phase Imaging Japan

27. 27 Market Feedback

28. 28 ICON in Recent Survey's “ ICON is one of three CRO’s cited most frequently as sponsor’s favourite CRO vendors” “Our confidence goes up that ICON is the right name to own in this environment, given their consistent quality” William Blair fourth survey of Pharma and Biotech Sponsors. “ ICON is a darling of the industry, the company's stunning growth in 2006 and 2007 surprised its peers. Now, the Dublin-based company is still outpacing just about everybody, but at a less accelerated clip.” Eric Coldwell Clinpage 2009 Master Providers

29. 29 Financial Performance

30. 30 Net Revenue CAGR of 30% since 2005 CAGR 30% * Lower end of 2009 Guidance (E)

31. 31 Earnings Per Share Growth CAGR 34% (E) * Lower end of 2009 Guidance

32. 32 Cash flow from Operations/Free Cash Flow * Estimate assumes DSO of approx 60 days. Historic periods FCF exclude Head-office construction costs

33. 33 Return on Equity

34. 34 Recent Financial Performance ($ millions) Quarter 1 09 31 Mar 0931 Mar 08% Increase Net Revenue2202019.2% Direct Costs1241139.7% SG & A EBITDA 61 35 60 28 1.2% 25% D & A8623% EBIT272225% Net Income211724% EPS (Inc SFAS 123R)35c28c25% Weighted Average no. of Shares (Inc SFAS123R) 59.7m60.1m(0.7%)

35. 35 Recent Financial Performance ($ millions) FY 08 31 Dec FY 2008 31 Dec FY 2007 % Increase Net Revenue86563137% Direct Costs48935438% SG & A EBITDA 248 128 189 88 32% 45% D & A281946% EBIT1006944% Net Income785640% EPS (Inc SFAS 123R)130c94c38% Weighted Average no. of Shares (Inc SFAS123R) 60.2m59.5m1.2%

36. 36 Summary Balance Sheet and Cash Flow ($ millions) Qtr ended Mar 31, 09 Full Year ended Dec 31, 08 Full Year ended Dec 31, 07 Full Year ended Dec 31, 06 Cash$96.9$101.1$118.6$102.9 Debt$99.2$105.4$94.8$5 Net Cash/Debt($2.3)($4.3)$23.8$97.9 Total assets$850.5$867.3$693.1$476.3 Total Liabilities$376.1$410.9$304.9$173.6 Shareholder’s equity$474.4$456.4$388.4$302.7 Cashflow from operations $24.7$81.3$42.9$50.4 Capital expenditures$8.1$67.9$75.4$31.5

37. 37 ICON Key Financial Metrics ($ millions) Qtr ended Mar 31, 09 Full Year ended Dec 31, 08 Full Year ended Dec 31, 07 Full Year ended Dec 31, 06 Sales Growth9.2%37%38%39% EPS Growth25%38%41%177% EBITDA Margin15.7%14.7%14%13.8% EBIT Margin12.2%11.5%11.0%10.5% ROE17.7%*17%14%13% * Annualised on the basis of Q1 net income

38. 38 ICON plc Historic Share Price Performance ICON S&P 500 Nasdaq Composite

39. 39 Top Global Clinical CRO - #4 Deep customer relationships Quality of staff Experienced Management team Excellent Reputation Solid market fundamentals Outstanding record of growth Strong balance sheet Investment Case Summary